전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,019 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleRochePhase 2

Omalizumab (Xolair®, Xolair® (Omalizumab))

Urticaria · Urticaria

#Urticaria#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#ClinicalStageIVCutaneousMelanoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleJules Bordet InstitutePhase 1

trastuzumab (Herceptin, Zr89-trastuzumab)

Breast Neoplasms; Secondary · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Active
CGTLimited DatastaleBeijing 302 HospitalPhase 2

allogeneic NK cells therapy (allogeneic NK cells therapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleInstitute of Hematology & Blood…Preclinical

anti-BCMA/GPRC5D bispecific CAR-T (anti-BCMA/GPRC5D bispecific CAR-T)

Extramedullary Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

anti-CD123 CAR-T treatment (anti-CD123 CAR-T treatment)

Acute Leukemia; Acute Leukemia in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleNational University Health Syst…Phase 1

anti-CD19 redirected NK cells (anti-CD19 redirected NK cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

anti-CD19/20-CAR vector-transduced T cells (anti-CD19/20-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

anti-CD19/22-CAR vector-transduced T cells (anti-CD19/22-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastalePeng LiuPhase 1

anti-CD19/BCMA CAR-T cells (anti-CD19/BCMA CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Progression · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19/BCMA U CAR T (anti-CD19/BCMA U CAR T)

Relapsed/Refractory Immune Nephropathy; Relapsed/Refractory Immune-mediated Kidney Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

anti-CD33 CART (anti-CD33 CART)

Relapsed Adult Myeloid Leukemia; Chemotherapy Refractory Adult Myeloid Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai General Hospital, Shan…Phase 1

anti-CD7 CAR-T cells (anti-CD7 CAR-T cells)

T Lymphoblastic Leukemia/Lymphoma; T-cell Acute Lymphoblastic Leukemia · T Lymphoblastic Leukemia/Lymphoma

#TLymphoblasticLeukemiaLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Advanced Solid Tumor · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleTongji HospitalPreclinical

apatinib plus camrelizumab (apatinib plus camrelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#monoclonal-antibody#Tongji
Trials 1Status Recruiting
CGTLimited DatastaleAeon Therapeutics (Shanghai) Co…Phase 1

autologous ET1402L1-CART cells (autologous ET1402L1-CART cells)

Hepatocellular Carcinoma; Liver Cancer · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued

48 / 51 pages

← PreviousNext →